<DOC>
	<DOCNO>NCT01555164</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multicenter study determine effect ranolazine add metformin glycemic control adult type 2 diabetes mellitus ( T2DM ) inadequately control despite current treatment stable metformin therapy addition diet exercise .</brief_summary>
	<brief_title>A Phase 3 Study Ranolazine Subjects With Type 2 Diabetes Who Are Inadequately Controlled Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Documented history T2DM Metformin therapy stable total daily dose ≥ 1500 mg ≤ 2550 mg addition diet exercise ≥ 8 week prior Screening Body mass index ( BMI ) 25 45 kg/m^2 , inclusive , Screening HbA1c within specify range Screening end Qualifying Period base current metformin dose Cpeptide ≥ 0.8 ng/mL Screening Fasting serum glucose ( FSG ) ≥ 130 mg/dL ( 7.2 mmol/L ) ≤ 240 mg/dL ( 13.3 mmol/L ) Screening end Qualifying Period Type 1 diabetes mellitus History diabetic ketoacidosis , ketosisprone diabetes , hyperosmolar hyperglycemic coma History severe hypoglycemia Any clinically significant cardiovascular cerebrovascular event ≤ 3 month prior Screening History congestive heart failure Corrected QT interval ( QTc ) &gt; 500 msec ECG Screening , personal family history QTc prolongation , congenital long QT syndrome , individual receive drug prolong QTc interval , Class Ia Class III antiarrhythmic agent , erythromycin , certain antipsychotic ( eg , ziprasidone ) Serum creatinine concentration ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female Screening Active liver disease and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3 x ULN and/or serum total bilirubin &gt; 2.0 mg/dL Use noninsulin antihyperglycemic therapy ( metformin ) 14 day ( consecutive ) 12 week ( 24 week thiazolidinediones ) prior Screening and/or use antihyperglycemic therapy metformin , dose , time 4 week prior randomization Treatment chronic insulin within 24 week prior Screening ( except one temporary period daily insulin injection longer 7 day ) Treatment strong moderate cytochrome P450 3A ( CYP3A ) inhibitor Pglycoprotein ( Pgp ) inhibitor within 14 day prior randomization Treatment CYP3A inducer Pgp inducer within 14 day prior randomization Treatment simvastatin lovastatin dose &gt; 20 mg &gt; 40 mg daily , respectively , within 14 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>